Skip to main content
CHENGDU SHENG NUO BIOTEC CO.,LTD. logo

CHENGDU SHENG NUO BIOTEC CO.,LTD. — Investor Relations & Filings

Ticker · 688117 ISIN · CNE1000050Q0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 546 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688117

About CHENGDU SHENG NUO BIOTEC CO.,LTD.

https://www.snbiopharm.com/

Chengdu Sheng Nuo Biotec Co., Ltd. is a specialized biotechnology enterprise focused on the research, development, and large-scale manufacturing of peptide drugs and related products. The company provides a comprehensive range of peptide active pharmaceutical ingredients (APIs) and finished dosage forms, covering therapeutic areas such as metabolic diseases, cardiovascular health, and reproductive medicine. Key products include Liraglutide, Semaglutide, and Teriparatide. Beyond its product portfolio, the company offers integrated CDMO services, supporting global pharmaceutical partners through process development, scale-up, and clinical-to-commercial manufacturing. Utilizing advanced solid-phase and liquid-phase synthesis technologies, the firm maintains rigorous quality management systems compliant with international GMP standards to ensure high-purity peptide production for domestic and international markets.

Recent filings

Filing Released Lang Actions
关于自愿披露醋酸特利加压素原料药完成美国FDA备案的公告
Regulatory Filings Classification · 85% confidence The document is a corporate announcement by the board that its subsidiary’s API (Terlipressin Acetate) has completed FDA DMF registration. It contains no financial statements, voting results, dividends, or management changes. It is a general regulatory/compliance announcement about product registration and risks. It fits the fallback category “Regulatory Filings (RNS).”
2026-05-21 Chinese
北京海润天睿律师事务所关于成都圣诺生物科技股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 90% confidence The document is a legal opinion letter (“法律意见书”) issued by a law firm regarding the convening, procedures, attendance, voting methods and results of the 2025 annual shareholders’ meeting. It primarily serves as a lawyer’s attestation and confirmation rather than the company’s own AGM materials or a standalone voting results announcement. Per the certification rule, such legal opinion or confirmation letters fall under the Regulatory Filings (RNS) category.
2026-05-15 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is titled “2025年年度股东会决议公告” and details the resolutions passed at the company’s annual shareholders’ meeting, including vote counts, percentages, and procedural compliance. It constitutes an official announcement of voting results at a general meeting rather than the meeting materials (AGM presentation) or the full annual report. Therefore, it is classified as a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-15 Chinese
关于召开2025年度暨2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 30% confidence The document is an announcement (“公告”) of the company’s upcoming 2025 annual and 2026 Q1 performance explanation meeting (业绩说明会). It contains logistics for an investor event (date, time, place, format, participants) and references where the actual annual and quarterly reports have been published, but it does not itself include detailed financial data, presentation slides, or substantive report content. It is not the report, proxy materials, or a transcript—rather, it is a general regulatory event notice that does not fit a more specific category. Therefore, it falls into the fallback “Regulatory Filings” category.
2026-05-12 Chinese
关于自愿披露替尔泊肽原料药完成美国FDA备案的公告
Regulatory Filings Classification · 80% confidence The document is a corporate announcement reporting that the company’s subsidiary has completed US FDA (DMF) filing for a pharmaceutical raw material. It does not contain financial results, voting outcomes, management changes, or audit opinions, nor is it a request for shareholder action. It is an operational/regulatory update. It falls under the miscellaneous regulatory announcement category rather than a specific financial report type.
2026-05-11 Chinese
2025年年度股东会会议资料
Regulatory Filings
2026-05-07 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.